System Models, Assays and Endpoint Parameters to Evaluate Anticancer Compounds During Preclinical Screening

E-ISSN： 1875-533x|21|35|3985-3998

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.21, Iss.35, 2014-11, pp. : 3985-3998

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Models and screening assays for drug discovery in osteoporosis

By Rissanen Jukka P Halleen Jussi M

Expert Opinion on Drug Discovery, Vol. 5, Iss. 12, 2010-12 ,pp. : 1163-1174

Informa Healthcare

Access to resources Recommend Favorite

A modified signal analysis system for end-point control during granulation

By Laicher A. Profitlich T. Schwitzer K. Ahlert D.

European Journal of Pharmaceutical Sciences, Vol. 5, Iss. 1, 1997-01 ,pp. : 7-14

Elsevier

Access to resources Recommend Favorite

Use of Partition Models to Evaluate Guidelines for Mixtures of Volatile Organic Compounds

By Hau K.M. Connell D.W. Richardson B.J.

Regulatory Toxicology and Pharmacology, Vol. 32, Iss. 1, 2000-08 ,pp. : 36-41

Academic Press

Access to resources Recommend Favorite

Anticancer Metallotherapeutics in Preclinical Development

Current Medicinal Chemistry, Vol. 18, Iss. 31, 2011-11 ,pp. : 4738-4752

Bentham Science Publishers

Access to resources Recommend Favorite

Disulfiram, and Disulfiram Derivatives as Novel Potential Anticancer Drugs Targeting the Ubiquitin Proteasome System in Both Preclinical and Clinical Studies

Current Cancer Drug Targets, Vol. 11, Iss. 3, 2011-03 ,pp. : 338-346

Bentham Science Publishers

Access to resources Recommend Favorite